AIG
RVNC

American International Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

American International Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-43,127
Closed -$212K – 2901
2024
Q1 		$212K Sell
43,127
-370
-0.9% -$2.19K ﹤0.01% 2112
2023
Q4 		$382K Buy
43,497
+1,863
+4% +$15.3K ﹤0.01% 1818
2023
Q3 		$478K Buy
41,634
+1,480
+4% +$28.5K ﹤0.01% 1633
2023
Q2 		$1.02M Buy
40,154
+1,187
+3% +$37K 0.01% 1243
2023
Q1 		$1.26M Buy
38,967
+775
+2% +$24.2K 0.01% 1126
2022
Q4 		$705K Buy
38,192
+4,132
+12% +$94.5K ﹤0.01% 1398
2022
Q3 		$920K Buy
34,060
+1,250
+4% +$25.4K 0.01% 1227
2022
Q2 		$453K Sell
32,810
-2,041
-6% -$31.4K ﹤0.01% 1666
2022
Q1 		$680K Sell
34,851
-2,453
-7% -$37.2K ﹤0.01% 1555
2021
Q4 		$609K Sell
37,304
-1,116
-3% -$18.6K ﹤0.01% 1693
2021
Q3 		$1.07M Sell
38,420
-913
-2% -$26.1K 0.01% 1407
2021
Q2 		$1.17K Buy
39,333
+2,656
+7% +$76.6K ﹤0.01% 1430
2021
Q1 		$1.02K Buy
36,677
+97
+0.3% +$2.68K ﹤0.01% 1446
2020
Q4 		$1.04K Sell
36,580
-1,050
-3% -$27.2K ﹤0.01% 1359
2020
Q3 		$946K Buy
37,630
+2,898
+8% +$76K ﹤0.01% 1272
2020
Q2 		$848K Buy
34,732
+4,176
+14% +$82.4K ﹤0.01% 1311
2020
Q1 		$452K Buy
30,556
+2,293
+8% +$47.4K ﹤0.01% 1486
2019
Q4 		$459K Buy
28,263
+457
+2% +$7.09K ﹤0.01% 1737
2019
Q3 		$361K Sell
27,806
-194
-0.7% -$2.37K ﹤0.01% 1832
2019
Q2 		$363K Buy
28,000
+3,609
+15% +$45.5K ﹤0.01% 1887
2019
Q1 		$384K Buy
24,391
+2,786
+13% +$48.3K ﹤0.01% 1858
2018
Q4 		$435K Sell
21,605
-166
-0.8% -$3.66K ﹤0.01% 1760
2018
Q3 		$541K Buy
21,771
+393
+2% +$10.7K ﹤0.01% 1847
2018
Q2 		$587K Buy
21,378
+4,173
+24% +$125K ﹤0.01% 1724
2018
Q1 		$530K Buy
17,205
+1,765
+11% +$56.8K ﹤0.01% 1681
2017
Q4 		$552K Buy
15,440
+402
+3% +$11.5K ﹤0.01% 1736
2017
Q3 		$414K Buy
15,038
+1,124
+8% +$27.2K ﹤0.01% 1867
2017
Q2 		$367K Buy
13,914
+1,324
+11% +$29.5K ﹤0.01% 1908
2017
Q1 		$262K Buy
12,590
+834
+7% +$17.1K ﹤0.01% 2016
2016
Q4 		$243K Sell
11,756
-31
-0.3% -$519 ﹤0.01% 2064
2016
Q3 		$191K Buy
11,787
+18
+0.2% +$261 ﹤0.01% 2197
2016
Q2 		$160K Buy
11,769
+1,161
+11% +$20.5K ﹤0.01% 2295
2016
Q1 		$185K Buy
10,608
+1,444
+16% +$29.4K ﹤0.01% 2852
2015
Q4 		$313K Sell
9,164
-561
-6% -$19.4K ﹤0.01% 2403
2015
Q3 		$289K Buy
9,725
+556
+6% +$16.9K ﹤0.01% 2473
2015
Q2 		$293K Buy
9,169
+3,761
+70% +$96.7K ﹤0.01% 2672
2015
Q1 		$112K Hold
5,408
– – ﹤0.01% 3466
2014
Q4 		$91.6K Buy
5,408
+862
+19% +$15.1K ﹤0.01% 3652
2014
Q3 		$87.9K Buy
4,546
+22
+0.5% +$573 ﹤0.01% 3650
2014
Q2 		$154K Buy
+4,524
New +$142K ﹤0.01% 3231

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American International Group's RVNC Position: Q2 2024 in Review

American International Group sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 43,127 shares — an estimated $212K sold.

American International Group first reported a position in RVNC in Q2 2014 and held it in 40 quarters. The position peaked at $1.26M in Q1 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

  • American International Group reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
  • American International Group sold 43,127 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $212K.
  • American International Group first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 40 quarters.
  • American International Group's Revance Therapeutics, Inc. position peaked at $1.26M in Q1 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.